Myriad's Says NCCN Updated Professional Guidelines Recommending Biomarker Testing For Unfavorable Intermediate And High-Risk Prostate Cancer Patients; Notes Co.'s Prolaris Test Was 'one of only two prognostic tests for prostate cancer' Recommended
Benzinga Newsdesk